Jazz Pharmaceuticals plc – Price Target Cut to $130.00 (JAZZ)
Investment analysts at R. F. Lafferty lowered their price target on shares of Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) from $140.00 to $130.00 in a note issued to investors on Friday, Analyst Ratings News reports. The firm currently has a “neutral” rating on the stock. R. F. Lafferty’s price objective suggests a potential downside of 2.76% from the company’s current price.
Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) traded down 8.56% on Friday, hitting $122.25. 738,525 shares of the company’s stock traded hands. Jazz Pharmaceuticals plc – has a 52 week low of $55.29 and a 52 week high of $176.60. The stock has a 50-day moving average of $136.4 and a 200-day moving average of $132.. The company has a market cap of $7.099 billion and a price-to-earnings ratio of 38.09.
Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) last posted its quarterly earnings results on Thursday, May 8th. The company reported $1.61 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.79 by $0.18. The company had revenue of $247.00 million for the quarter, compared to the consensus estimate of $254.86 million. During the same quarter in the previous year, the company posted $1.37 earnings per share. The company’s revenue for the quarter was up 25.8% on a year-over-year basis. Analysts expect that Jazz Pharmaceuticals plc – will post $8.20 EPS for the current fiscal year.
Several other analysts have also recently commented on the stock. Analysts at Leerink Swann cut their price target on shares of Jazz Pharmaceuticals plc – from $170.00 to $165.00 in a research note on Friday. Separately, analysts at UBS AG cut their price target on shares of Jazz Pharmaceuticals plc – from $195.00 to $180.00 in a research note on Friday. Finally, analysts at Citigroup Inc. cut their price target on shares of Jazz Pharmaceuticals plc – from $195.00 to $165.00 in a research note on Friday. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Jazz Pharmaceuticals plc – presently has a consensus rating of “Buy” and a consensus target price of $166.82.
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.